行情

REPH

REPH

Recro Pharma
NASDAQ

实时行情|Nasdaq Last Sale

7.03
-1.14
-13.95%
盘后: 7.03 0 0.00% 16:11 04/01 EDT
开盘
8.00
昨收
8.17
最高
8.05
最低
6.85
成交量
77.99万
成交额
--
52周最高
19.21
52周最低
5.15
市值
1.65亿
市盈率(TTM)
37.04
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测REPH价格均价为18.25,最高价位23.00,最低价为14.00。

EPS

REPH 新闻

更多
  • 新华社:新冠肺炎疫情或致美国制造业深陷衰退危机
  • 新华网 · 1小时前
  • 沪指低开高走 疫情数据双重打击、隔夜美股重挫4.4%
  • 新浪财经 · 1小时前
  • 菲律宾总统下令隔离期间制造麻烦者格杀勿论
  • 新浪财经 · 1小时前
  • 澳洲拟拨款16亿澳元 疫情期间托儿免费
  • 新浪财经 · 1小时前

所属板块

制药
-2.46%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

REPH 简况

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
展开

微牛提供Recro Pharma Inc(NASDAQ-REPH)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的REPH股票新闻,以帮助您做出投资决策。